Sirukumab
Sirukumab
Sirukumab (pronunciation: si-ru-ku-mab) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It was developed by Janssen Biotech, a pharmaceutical company that is a subsidiary of Johnson & Johnson.
Etymology
The name "Sirukumab" is derived from the International Nonproprietary Names (INN), in which 'mab' is used as a suffix for monoclonal antibodies. The 'siru' part of the name does not have a specific meaning and is used for distinction among other monoclonal antibodies.
Mechanism of Action
Sirukumab works by targeting and inhibiting the interleukin-6 (IL-6) cytokine, a protein that plays a key role in the inflammatory response of the immune system. By blocking the action of IL-6, Sirukumab can help reduce inflammation and slow the progression of rheumatoid arthritis.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety and efficacy of Sirukumab. However, in 2017, the Food and Drug Administration (FDA) rejected the application for Sirukumab due to safety concerns.
Related Terms
- Monoclonal Antibodies: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Rheumatoid Arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Interleukin-6: A cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
- Janssen Biotech: A pharmaceutical company that developed Sirukumab.
- Johnson & Johnson: A multinational corporation that includes more than 250 subsidiaries with operations in 60 countries and products sold in over 175 countries.
External links
- Medical encyclopedia article on Sirukumab
- Wikipedia's article - Sirukumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski